NCT03950609 2026-03-19
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT07477548 2026-03-17
A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Yonsei University
Phase 2 Not yet recruiting
NCT04485559 2026-03-16
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
Phase 1 Recruiting
NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT05012371 2026-03-05
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05843253 2026-03-04
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT07435584 2026-02-27
EVER-RECODE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT04199026 2026-02-19
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT06955169 2026-02-17
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
NCT02397083 2026-02-13
LEVER
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07407517 2026-02-12
POLARIS
Fudan University
Phase 3 Not yet recruiting
NCT02143726 2026-02-11
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT03008408 2026-02-11
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07340541 2026-02-09
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT02520063 2026-02-06
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT02407509 2026-01-29
RAF/MEK
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT01087554 2026-01-16
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT03065387 2026-01-12
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07318324 2026-01-06
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting